Medtronic PLC

NYSE MDT

Download Data

Medtronic PLC Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the quarter ending April 30, 2024: 18.36%

Medtronic PLC Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is 18.36% for the quarter ending April 30, 2024, a 163.60% change year over year. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Medtronic PLC Current Liabilities to Total Liabilities Ratio for the quarter ending April 30, 2023 was 0.23, a -28.88% change year over year.
  • Medtronic PLC Current Liabilities to Total Liabilities Ratio for the quarter ending April 30, 2022 was 0.32, a 57.92% change year over year.
  • Medtronic PLC Current Liabilities to Total Liabilities Ratio for the quarter ending April 30, 2021 was 0.21, a -21.21% change year over year.
  • Medtronic PLC Current Liabilities to Total Liabilities Ratio for the quarter ending April 30, 2020 was 0.26, a 21.33% change year over year.
NYSE: MDT

Medtronic PLC

CEO Mr. Geoffrey Straub Martha
IPO Date Jan. 13, 1978
Location Ireland
Headquarters 20 On Hatch, Dublin, Ireland, 2
Employees 95,000
Sector Healthcare
Industry Medical devices
Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Similar companies

ABT

Abbott Laboratories

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email